glp-1 cancer risk Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management Risk of Esophageal and Gastric

Reduced Fat Absorption: GLP-1 medications may limit the absorption of dietary fats, decreasing overall calorie intake from meals

A study in The New England Journal of Medicine found that 59 percent of patients with NASH (non-alcoholic steatohepatitis) who took a high dose of semaglutide for 72 weeks saw improvement without worsening of fibrosis (or scarring)

EU consumers: buyers in the European Union have consumer rights under the EU Omnibus Directive, the Distance Selling Directive, and applicable consumer protection law that may differ from US standards

2013 3:e001986

Tirzepatide (Subcutaneous Route)

Longer-Term Risks of GLP-1RA